Skip to main content
. 2021 Aug 11;70:103527. doi: 10.1016/j.ebiom.2021.103527

Table 4.

Multiplex and Xpert MTB/RIF diagnostic performances relative to sputum culture.

Multiplex RT-PCR Xpert MTB-RIF


All participants (N=190)
Sensitivity (%) [CI] 80·4 [66·8-89·3] 93·4 [82·85-97·7]
Specificity (%) [CI] 85·7 [77·7-91·1] 61·9 [52·3-70·6]
PPV (%) [CI] 71·1 [57·7-81·6] 51·8 [41·2-62·2]
NPV (%) [CI] 90·9 [83·6-95·1] 95·5 [87·8-98·4]
TB Patient Naïve to treatment (N=30) Sensitivity (%) [CI] 82·4 [58·9–93·8] 94·1 [73·0–98·9]
Specificity (%) [CI] 90·9 [62·2–98·3] 81·8 [52·3–94·8]
PPV (%) [CI] 93·3 [70·1–98·8] 88·9 [67·2–96·9]
NPV (%) [CI] 76·9 [49·7–91·8] 90.0 [59·5–98·2]
HIV Patient (N=36) Sensitivity (%) [CI] 71·4 [52·9–84·7] 96·4 [82·2–99·3]
Specificity (%) [CI] 96·2 [81·1–99·3] 76.9 [57·9–88·9]
PPV (%) [CI] 95·2 [77·3–99·1] 81·8 [65·6–91·3]
NPV (%) [CI] 75·8 [58·9 – 87·1] 95·2 [77·3–99·1]
Treatment failure, retreatment and NTM suspected patients (N=77) Sensitivity (%) [CI] 75·0 [50·5-89·8] 87·5 [63·9-96·5]
Specificity (%) [CI] 71·1 [56·6-82·2] 37·7 [25·1-52·3]
PPV (%) [CI] 48·0 [30·0-66·5] 33·3 [21·0-48·4]
NPV (%) [CI] 88·8 [74·6-95·5] 89·4 [68·6-97·0]
All (without treatment failure participants) (N=113) Sensitivity (%) [CI] 83·3 [66·4-92·6] 96·7 [83·3-99·4]
Specificity (%) [CI] 96·6 [88·6-99·0] 80·0 [68·2-88·1]
PPV (%) [CI] 92·5 [82·3-96·5] 70·7 [55·5-82·3]
NPV (%) [CI] 92·2 [82·7-96·5] 97·9 [89·3-99·6]

CI: confidence Interval; PPV: Positive Predictive Value; NPV: Negative Predictive Value